Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.

Background: This study describes the conditions of use of ceftolozane/tazobactam (C/T) and associated outcomes in French hospital settings.
Methods: This was a prospective, multicenter, French observational study. Patients who received at least 1 dose of C/T were included and followed up as per routine clinical practice, until stop of C/T.
Results: A total of 260 patients were enrolled between October 2018 and December 2019 in 30 centers across France. Of these, 177 (68.0%) received C/T as per indication of usage following the results of the antibiogram (documented cases). Among documented patients, the mean age was 61.8 years, 73.4% were males, and 93.8% presented with multidrug-resistant (MDR) bacteria at inclusion. C/T was most frequently prescribed for pneumonia (48.6%), bacteremia (14.7%), complicated intra-abdominal infections (13.0%), or complicated urinary tract infections (9.6%). Pseudomonas aeruginosa was the species most frequently isolated with 212 strains from 155 patients, and 96.2% of these strains were susceptible to C/T. The median duration of C/T treatment was 16.1 days (1-115, n = 176). Complete or partial cure was achieved in 71.7% of patients, C/T was discontinued upon adaptation to microbiology results in 11.3% of patients for the following reasons: treatment failure in 2.8%, death in 4.0%, adverse events in 1.7%, and other in 8.5%.
Conclusions: This is the first prospective observational study of C/T utilization in a health care setting enrolling many patients in France. C/T demonstrated a high rate of clinical effectiveness in MDR infections, confirming it as an effective treatment option for complicated infections in a high-risk population.
Competing Interests: Potential conflicts of interest. J.F.T. has received research funding from ad boards: MSD, PFIZER, GILEAD, MENARINI, BD, ASPEN, SHIONOGI; has reported research grants from MSD, PFIZER, THERMOFISCHER; and has been a speaker/advisor for MSD, PFIZER, BIOMERIEUX, QIAGEN, SHIONOGI, GILEAD, BD. B.C. has reported research funding from SANOFI, MSD, SHIONOGI; and has been a speaker/advisor for MSD, SANOFI, ADVANZ PHARMA, BIOMERIEUX. R.R. has been a speaker/advisor PFIZER, SHIONOGI; and has received research funding from ad boards from MSD. B.A., X.B., I.B., and C.M. were employees of MSD France at the time the study was conducted. D.B. has received research funding for ad boards from MSD. All other authors report no potential conflicts.
(© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)